Thermo Fisher Scientific Inc (TMO) 157.66 $TMO The

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Thermo Fisher Scientific Inc (TMO) 157.66 $TMO

The Cooper Companies Set to Join the S&P 500; Northwestern and NuVasive to Join S&P MidCap 400; SPS Commerce and Fox Factory to Join S&P SmallCap 600
PR Newswire - Tue Sep 20, 5:15PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices effective after the close of trading on Thursday, September 22:
SPGI: 126.83 (-0.73), TMO: 157.66 (+2.24), SPSC: 73.42 (+1.50), NWE: 60.10 (+0.16), MAR: 69.75 (-0.39), FOXF: 22.12 (+0.30), NUVA: 68.06 (+1.06), COO: 184.50 (-1.68), FEIC: 106.89 (+0.09), HOT: 77.05 (-0.20)

Watch for Thermo Fisher Scientific to Potentially Pullback After Gaining 1.19% Yesterday
Comtex SmarTrend(R) - Tue Sep 20, 12:38PM CDT
Thermo Fisher Scientific (NYSE:TMO) traded in a range yesterday that spanned from a low of $150.46 to a high of $152.53. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $151.28 on volume of 694,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TMO: 157.66 (+2.24)

Thermo Fisher Scientific Set to Possibly Pullback After Yesterday's Rally of 1.19%
Comtex SmarTrend(R) - Tue Sep 20, 12:36PM CDT
Thermo Fisher Scientific (NYSE:TMO) traded in a range yesterday that spanned from a low of $150.46 to a high of $152.53. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $151.28 on volume of 694,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TMO: 157.66 (+2.24)

Thermo Fisher Adds FEI Co., Inorganic Expansion Continues
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 6:57AM CDT
Thermo Fisher Scientific, Inc. (TMO) recently closed the acquisition of FEI Company, Inc.
ABMD: 126.37 (-0.53), TMO: 157.66 (+2.24), CPHD: 52.50 (-0.03), CRY: 18.56 (+0.28)

Thermo Fisher Scientific Completes Acquisition of FEI Company
BusinessWire - Mon Sep 19, 7:01PM CDT
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of FEI Company, Inc. (NASDAQ: FEIC), the leader in high-performance electron microscopy, for $107.50 per share in cash, or a total purchase price of approximately $4.2 billion. The completion of the transaction follows the receipt of all required regulatory approvals. The business will become part of Thermo Fisher's Analytical Instruments Segment.
TMO: 157.66 (+2.24), FEIC: 106.89 (+0.09)

Thermo Fisher Scientific Rises 1.24% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Sep 15, 12:44PM CDT
Thermo Fisher Scientific (NYSE:TMO) traded in a range yesterday that spanned from a low of $147.95 to a high of $149.98. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $147.87 on volume of 853,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TMO: 157.66 (+2.24)

Look for Shares of Thermo Fisher Scientific to Potentially Pullback after Yesterday's 1.24% Rise
Comtex SmarTrend(R) - Thu Sep 15, 12:42PM CDT
Thermo Fisher Scientific (NYSE:TMO) traded in a range yesterday that spanned from a low of $147.95 to a high of $149.98. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $147.87 on volume of 853,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TMO: 157.66 (+2.24)

Thermo Fisher Scientific Prices Offering of Senior Notes
BusinessWire - Wed Sep 14, 3:57PM CDT
Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of $1.2 billion aggregate principal amount of its 2.950% senior notes due 2026 at the issue price of 98.787% of the principal amount.
TMO: 157.66 (+2.24)

SmarTrend Watching for Potential Rebound in Shares of Thermo Fisher Scientific After 3.48% Loss
Comtex SmarTrend(R) - Fri Sep 09, 1:40PM CDT
Thermo Fisher Scientific (NYSE:TMO) traded in a range yesterday that spanned from a low of $145.13 to a high of $148.52. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $150.29 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TMO: 157.66 (+2.24)

Look for Shares of Thermo Fisher Scientific to Potentially Rebound after Yesterday's 3.48% Sell Off
Comtex SmarTrend(R) - Fri Sep 09, 1:38PM CDT
Thermo Fisher Scientific (NYSE:TMO) traded in a range yesterday that spanned from a low of $145.13 to a high of $148.52. Yesterday, the shares fell 3.5%, which took the trading range below the 3-day low of $150.29 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TMO: 157.66 (+2.24)

Healthcare Stocks Under Review -- Exact Sciences, Great Basin Scientific, Agilent Technologies, and Thermo Fisher Scientific
PR Newswire - Thu Sep 08, 6:30AM CDT
The Medical Laboratories market continues to grow at a fast pace due to scientific advances and aging population. This segment includes bacteriological, histological, pathological and chemical analysis, urinalysis, and dental and medical X-rays. Stocks under assessment on Stock-Callers.com today are: Exact Sciences Corp. (NASDAQ: EXAS), Great Basin Scientific Inc. (NASDAQ: GBSN), Agilent Technologies Inc. (NYSE: A), and Thermo Fisher Scientific Inc. (NYSE: TMO). Learn more about these stocks by downloading their free research reports in PDF format at:
GBSN: 2.97 (-0.45), TMO: 157.66 (+2.24), A: 46.67 (+0.63), EXAS: 21.45 (-0.01)

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes
BusinessWire - Wed Sep 07, 8:24PM CDT
Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has priced an offering of EUR1.0 billion aggregate principal amount of its 0.750% senior notes due 2024 and EUR600 million aggregate principal amount of its 1.375% senior notes due 2028 at the issue prices of 99.122% of the principal amount and 99.748% of the principal amount, respectively.
TMO: 157.66 (+2.24)

Thermo Fisher Scientific to Present at the Morgan Stanley Global Healthcare Conference on September 14, 2016
BusinessWire - Tue Sep 06, 7:30AM CDT
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016, at 8:10 a.m. (EDT) at the Grand Hyatt New York, New York.
TMO: 157.66 (+2.24), MS: 32.24 (+0.32)

FEI Shareholders Approve Thermo Fisher Deal (Revised)
Urmimala Biswas - Zacks Investment Research - Thu Sep 01, 4:44PM CDT
Shareholders of FEI recently approved mega $4.2 billion deal to be acquired by Thermo Fisher Scientific.
BABY: 44.38 (+0.59), MASI: 60.32 (+0.47), TMO: 157.66 (+2.24), IDXX: 113.09 (+1.02)

Thermo Fisher Shareholders Approve FEI Deal, Grows in Electron Microscopy (Revised)
Urmimala Biswas - Zacks Investment Research - Thu Sep 01, 2:59PM CDT
Shareholders of Thermo Fisher recently approved its previously announced mega $4.2 billion acquisition of FEI Company.
BABY: 44.38 (+0.59), MASI: 60.32 (+0.47), TMO: 157.66 (+2.24), IDXX: 113.09 (+1.02)

Stock Market News for September 01, 2016
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:10AM CDT
Decline in energy shares weighed on benchmarks on Wednesday.
CHRW: 69.25 (+0.71), ADP: 89.46 (+0.58), TMO: 157.66 (+2.24), WY: 32.08 (+1.74), COST: 153.15 (+0.45), XOM: 83.54 (+0.24), GOOGL: 815.95 (+10.92), CVX: 99.98 (+0.35), CRM: 74.59 (+0.41)

Thermo Fisher Closes FEI Deal, Grows in Electron Microscopy
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 6:42AM CDT
Thermo Fisher Scientific, Inc. (TMO) recently completed its earlier announced mega $4.2 billion acquisition of FEI Company.
BABY: 44.38 (+0.59), MASI: 60.32 (+0.47), TMO: 157.66 (+2.24), IDXX: 113.09 (+1.02)

FEI Shareholders Approve Acquisition by Thermo Fisher Scientific
GlobeNewswire - Tue Aug 30, 3:19PM CDT
FEI Company (Nasdaq:FEIC) today announced that at the special meeting of FEI's shareholders held on August 30, 2016, its shareholders overwhelmingly approved the previously announced acquisition of FEI by Thermo Fisher Scientific Inc. (NYSE:TMO). The transaction is expected to be completed by the end of 2016, subject to the satisfaction of customary closing conditions, including applicable regulatory approvals.
TMO: 157.66 (+2.24), FEIC: 106.89 (+0.09)

Illumina Rallies on Rumors of Takeover by Thermo Fisher
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:42AM CDT
Reportedly, Thermo Fisher (TMO) has made an all-stock offer of $30 billion to acquire Illumina (ILMN), which currently has a market cap of over $25 billion.
GWPH: 109.76 (+1.80), TMO: 157.66 (+2.24), QDEL: 22.79 (+0.91), ILMN: 179.34 (+0.89)

Watch for Thermo Fisher Scientific to Potentially Rebound After Falling 1.21% Yesterday
Comtex SmarTrend(R) - Fri Aug 12, 1:44PM CDT
Thermo Fisher Scientific (NYSE:TMO) traded in a range yesterday that spanned from a low of $155.05 to a high of $156.84. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $155.60 on volume of 353,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TMO: 157.66 (+2.24)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 352

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 377

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading